Efficacy of nebulized salbutamol in transient tachypnea of the newborn: A systematic review and meta-analysis
- 1Princess Srisavangavadhana Faculty of Medicine, Chulabhorn Royal Academy, Bangkok, Thailand
- 2Department of Pharmacology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
- 3Clinical Research Center for Food and Herbal Product Trials and Development (CR-FAH), Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
Abstract
Transient tachypnea of the newborn (TTN) commonly affects near- and full-term infants and often requires respiratory support. The use of nebulized salbutamol to improve respiratory outcomes has been of interest, though its clinical efficacy remains controversial. This systematic review and meta-analysis aimed to evaluate whether nebulized salbutamol improves clinical outcomes in affected infants. We searched PubMed, Scopus, Embase, and the Cochrane Library for randomized controlled trials (RCTs) evaluating the efficacy of nebulized salbutamol in infants with TTN. We used a random-effects model to calculate mean differences (MDs) with 95% confidence intervals (CIs). Twenty-five studies were included in the systematic review, comprising seventeen RCTs for meta-analysis involving 1,317 infants. The analysis showed that salbutamol significantly decreased the duration of respiratory support (MD: −14.85 hours; 95% CI [−25.05, −4.65]; p = 0.004), duration of continuous positive airway pressure (MD: −18.19 hours; 95% CI [−30.03, −6.35]; p = 0.003), duration of oxygen requirement (MD: −24.57 hours; 95% CI [−35.03, −14.10]; p < 0.001), and length of hospitalization (MD: −1.17 days; 95% CI [−1.69, −0.65]; p < 0.001). However, there was no significant decrease in duration of tachypnea (MD: −9.93 hours; 95% CI [−25.42, 5.56]; p = 0.21) or duration of neonatal intensive care unit stay (MD: −0.84 days; 95% CI [−2.62, 0.94]; p = 0.36). Subgroup analysis for respiratory support duration showed no significant effect in infants with clinical score of TTN < 5 (MD: −10.88 hours; 95% CI [−24.48, 2.73]; p = 0.12), while the certainty of evidence for all outcomes was low to very low. Nebulized salbutamol may improve clinical outcomes relevant to the evolution of the disease in TTN infants, with potential benefits in certain subgroups such as those with greater disease severity, though the available evidence is of low to very low certainty. Therefore, our confidence in its efficacy in treating TTN remains limited.
Related
- Heat Kernel Estimates for Random Walks with Killing on Transient Graphs
- The randomly oriented Manhattan lattice in 2D is transient
- Geometric approximation for the number of returns of a transient Markov chain to its origin
- Linear Response Theory for Jump-Driven Stochastic Systems: Transient Statistics and Escape Dynamics
- A Multirate Transient Simulation Technique for Circuits described by Integro-Differential Equations
BibTeX
@article{phattraprayoon2026efficacy,
title = {{Efficacy of nebulized salbutamol in transient tachypnea of the newborn: A systematic review and meta-analysis}},
author = {Nanthida Phattraprayoon and Nut Koonrungsesomboon and Mingkwan Na Takuathung},
journal = {PLOS One},
year = {2026},
month = oct,
doi = {10.1371/journal.pone.0359663},
url = {https://doi.org/10.1371/journal.pone.0359663},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Efficacy of nebulized salbutamol in transient tachypnea of the newborn: A systematic review and meta-analysis
AU - Nanthida Phattraprayoon
AU - Nut Koonrungsesomboon
AU - Mingkwan Na Takuathung
PY - 2026
DA - 2026/10/01
JO - PLOS One
DO - 10.1371/journal.pone.0359663
UR - https://doi.org/10.1371/journal.pone.0359663
AB - Transient tachypnea of the newborn (TTN) commonly affects near- and full-term infants and often requires respiratory support. The use of nebulized salbutamol to improve respiratory outcomes has been of interest, though its clinical efficacy remains controversial. This systematic review and meta-analysis aimed to evaluate whether nebulized salbutamol improves clinical outcomes in affected infants. We searched PubMed, Scopus, Embase, and the Cochrane Library for randomized controlled trials (RCTs) evaluating the efficacy of nebulized salbutamol in infants with TTN. We used a random-effects model to calculate mean differences (MDs) with 95% confidence intervals (CIs). Twenty-five studies were included in the systematic review, comprising seventeen RCTs for meta-analysis involving 1,317 infants. The analysis showed that salbutamol significantly decreased the duration of respiratory support (MD: −14.85 hours; 95% CI [−25.05, −4.65]; p = 0.004), duration of continuous positive airway pressure (MD: −18.19 hours; 95% CI [−30.03, −6.35]; p = 0.003), duration of oxygen requirement (MD: −24.57 hours; 95% CI [−35.03, −14.10]; p < 0.001), and length of hospitalization (MD: −1.17 days; 95% CI [−1.69, −0.65]; p < 0.001). However, there was no significant decrease in duration of tachypnea (MD: −9.93 hours; 95% CI [−25.42, 5.56]; p = 0.21) or duration of neonatal intensive care unit stay (MD: −0.84 days; 95% CI [−2.62, 0.94]; p = 0.36). Subgroup analysis for respiratory support duration showed no significant effect in infants with clinical score of TTN < 5 (MD: −10.88 hours; 95% CI [−24.48, 2.73]; p = 0.12), while the certainty of evidence for all outcomes was low to very low. Nebulized salbutamol may improve clinical outcomes relevant to the evolution of the disease in TTN infants, with potential benefits in certain subgroups such as those with greater disease severity, though the available evidence is of low to very low certainty. Therefore, our confidence in its efficacy in treating TTN remains limited.
SN - 1932-6203
ER -